Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort.
Maponga TG., McNaughton AL., Van Schalkwyk M., Hugo S., Nwankwo C., Taljaard J., Mokaya J., Smith DA., van Vuuren C., Goedhals D., Gabriel S., Andersson MI., Preiser W., van Rensburg C., Matthews PC.
OBJECTIVES:Prompted by international targets for elimination of hepatitis B virus (HBV), we set out to characterise individuals with HBV monoinfection vs. those coinfected with HBV/HIV, to evaluate the impact of therapy and to guide improvements in clinical care. METHODS:We report observational data from a real world cross-sectional cohort of 115 adults with CHB, at a university hospital in Cape Town, South Africa. HIV coinfection was present in 39 (34%) subjects. We recorded cross-sectional demographic, clinical and laboratory data. RESULTS:Compared to those with HIV coinfection, HBV monoinfected adults were less likely to be HBeAg-positive (p=0.01), less likely to have had assessment with elastography (p<0.0001), and less likely to be on antiviral treatment (p<0.0001); they were more likely to have detectable HBV viraemia (p=0.04), and more likely to have features of liver disease including moderate/severe thrombocytopaenia (p=0.007), elevated bilirubin (p=0.004), and elevated APRI score (p=0.02). Three cases of hepatocellular carcinoma all arose in HBV monoinfection. CONCLUSIONS:Our data demonstrate that individuals with HBV monoinfection may be disadvantaged compared to those with HIV coinfection, highlighting potential systematic inequities in referral, monitoring and treatment.